1 / 13

Trial profile

Trial profile. John A Dormandy et al. Lancet 2005;366:1279-89. Baseline characteristics. John A Dormandy et al. Lancet 2005;366:1279-89. Macrovascular morbidity at study entry and associated medications. John A Dormandy et al. Lancet 2005;366:1279-89.

oren-spence
Télécharger la présentation

Trial profile

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile John A Dormandy et al. Lancet 2005;366:1279-89

  2. Baseline characteristics John A Dormandy et al. Lancet 2005;366:1279-89

  3. Macrovascular morbidity at study entry and associated medications John A Dormandy et al. Lancet 2005;366:1279-89

  4. Kaplan-Meier curve of time to primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

  5. Kaplan-Meier curve of time to main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

  6. Numbers of first events contributing to the primary composite and main secondary endpoints John A Dormandy et al. Lancet 2005;366:1279-89

  7. Effect of pioglitazone and placebo on each component of the primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

  8. Hazard associated with relevant baseline characteristics for the main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

  9. Change in proportion of patients using concomitant medications John A Dormandy et al. Lancet 2005;366:1279-89

  10. Kaplan-Meier curve of time to permanent insulin use John A Dormandy et al. Lancet 2005;366:1279-89

  11. Change in laboratory data from baseline to final visit John A Dormandy et al. Lancet 2005;366:1279-89

  12. Serious adverse event summary John A Dormandy et al. Lancet 2005;366:1279-89

  13. Reports of heart failure John A Dormandy et al. Lancet 2005;366:1279-89

More Related